Updates are available Correction dated 2025-07-23

Article History

Received: 19 February 2025

Accepted: 30 April 2025

First Online: 19 May 2025

Change Date: 23 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s12325-025-03316-2

Declarations

:

: Njira L. Lugogo has received consultancy fees for participation in advisory boards from Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals; has received honoraria for nonspeaker bureau presentations from AstraZeneca and GSK; has received speaker fees (own content) from NIOX; has received travel support from AstraZeneca; and has received research support to her institution from Amgen, AstraZeneca, Avillion, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals. Praveen Akuthota has received consultancy fees and research support from Amgen, AstraZeneca, Connect Biopharma, GSK, Regeneron and Sanofi; has received research support from the American Partnership for Eosinophilic Disorders, the National Institutes of Health and Regeneron Pharmaceuticals; has received royalties from UpToDate; and has received fees for continuing medical education presentations from Advancing Knowledge in Healthcare, Medscape, MJH Life Sciences, PeerView, PRIME Continuing Medical Education, Projects in Knowledge, Rockpointe and Vindico Medical Education. Kaharu Sumino has received consultancy fees for participation in an advisory board from AstraZeneca. Sameer K. Mathur has received consultancy fees from AstraZeneca, GSK and Regeneron Pharmaceuticals, and has received fees for presentations from AstraZeneca and GSK. Autumn F. Burnette has received consultancy fees for participation in advisory boards and panel presentations from Amgen, AstraZeneca, GSK, Regeneron Pharmaceuticals and Sanofi, and has received speaker bureau fees from Amgen, AstraZeneca, Regeneron Pharmaceuticals and Sanofi. Andrew W. Lindsley and Jean-Pierre Llanos are employees of Amgen and own stock in Amgen. Claudio Marchese, Christopher S. Ambrose and Benjamin Emmanuel are employees of AstraZeneca and may own stock or stock options in AstraZeneca.

: The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. Approvals from the Advarra Central Institutional Review Board (MD, USA and ON, Canada) and local independent ethics committees were obtained for all study sites (see supplementary material for a full list of ethics committees and Institutional Review Boards that covered the study sites). All participants provided written informed consent at the start of the study.